← Back to Search

Transcutaneous Electrical Nerve Stimulator

Quell Wearable Device for Chronic Pain

N/A
Recruiting
Led By Robert N. Jamison, Ph.D.
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ages 21 and older
Average 4 or greater on pain intensity scale of 0 to 10
Must not have
Acute osteomyelitis or acute bone disease
Diagnosis of cancer or any other malignant disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-month follow-up
Awards & highlights

Summary

This trial will test the effectiveness of a device called a Quell for people with multiple chronic pain conditions.

Who is the study for?
This trial is for adults over 21 with chronic pain from multiple conditions like headaches, joint or back pain. Participants need a smartphone to use specific apps and must understand English. They should have ongoing pain not due to progressive diseases like cancer or MS, rate their pain 4+ on a scale of 0-10, and meet certain sensitivity criteria.
What is being tested?
The study tests the Quell device's effectiveness in relieving chronic pain through electrical nerve stimulation. It compares two intensities: high and low. Participants will use the device alongside mobile apps that track their experience.
What are the potential side effects?
Potential side effects may include skin irritation where the device is worn, discomfort from electrical stimulation, muscle twitching, or an increase in pain if settings are not properly adjusted.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 21 years old or older.
Select...
My average pain level is 4 or more on a scale of 0 to 10.
Select...
I have been diagnosed with several chronic pain conditions.
Select...
My pain has lasted for more than 3 months.
Select...
My pain is not caused by any other worsening disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a recent bone infection or disease.
Select...
I have been diagnosed with cancer or another type of malignant disease.
Select...
I need urgent surgery for my pain condition.
Select...
I have open cuts or sores.
Select...
I have Reynaud's syndrome.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-month follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The Brief Pain Inventory Interference Scale (BPI)
Secondary study objectives
Healthcare Utilization
Hospital Anxiety and Depression Scale (HADS)
MasterMyPain App
+8 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: High Intensity StimulationActive Control1 Intervention
Patients will be randomly assigned to the High Intensity Quell group and will receive higher intensity stimulation every day for 12 weeks.
Group II: Low Intensity StimulationPlacebo Group1 Intervention
Patients will be randomly assigned to the Low intensity Quell group and will receive lower intensity stimulation every day for 12 weeks.

Find a Location

Who is running the clinical trial?

NeuroMetrix, Inc.Industry Sponsor
6 Previous Clinical Trials
315 Total Patients Enrolled
1 Trials studying Chronic Pain
30 Patients Enrolled for Chronic Pain
Brigham and Women's HospitalLead Sponsor
1,653 Previous Clinical Trials
11,490,920 Total Patients Enrolled
20 Trials studying Chronic Pain
1,932 Patients Enrolled for Chronic Pain
Robert N. Jamison, Ph.D.Principal InvestigatorBrigham and Women's Hospital

Media Library

Quell Wearable Device (Transcutaneous Electrical Nerve Stimulator) Clinical Trial Eligibility Overview. Trial Name: NCT05540002 — N/A
Chronic Pain Research Study Groups: Low Intensity Stimulation, High Intensity Stimulation
Chronic Pain Clinical Trial 2023: Quell Wearable Device Highlights & Side Effects. Trial Name: NCT05540002 — N/A
Quell Wearable Device (Transcutaneous Electrical Nerve Stimulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05540002 — N/A
~0 spots leftby Oct 2024